Last reviewed · How we verify
Nicoderm Patch
Nicotine binds to nicotinic acetylcholine receptors in the brain, providing nicotine replacement to reduce cravings and withdrawal symptoms during smoking cessation.
Nicotine binds to nicotinic acetylcholine receptors in the brain, providing nicotine replacement to reduce cravings and withdrawal symptoms during smoking cessation. Used for Smoking cessation aid.
At a glance
| Generic name | Nicoderm Patch |
|---|---|
| Also known as | Nicoderm 21mg, NPN: #02093146, Nicoderm 14mg, NPN: #02093138, Nicoderm 7mg, NPN: #02093111, NRT patch, nicotine patch |
| Sponsor | US Department of Veterans Affairs |
| Drug class | Nicotine replacement therapy (NRT) |
| Target | Nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Addiction Medicine / Smoking Cessation |
| Phase | FDA-approved |
Mechanism of action
Nicoderm is a transdermal patch that delivers nicotine across the skin into the bloodstream. By activating nicotinic acetylcholine receptors, it mimics the effects of smoking without the harmful combustion byproducts, thereby reducing the urge to smoke and alleviating withdrawal symptoms such as irritability, anxiety, and difficulty concentrating.
Approved indications
- Smoking cessation aid
Common side effects
- Skin irritation at patch site
- Headache
- Nausea
- Dizziness
- Sleep disturbances
- Vivid dreams
Key clinical trials
- Partnering With Food Bank to Provide Tobacco Treatment to Underserved Smokers (NA)
- Defining Neurobiological Links Between Substance Use and Mental Illness (NA)
- Exenatide for Smoking Cessation and Prevention of Weight Gain (PHASE2)
- A Study Of Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation (PHASE2, PHASE3)
- Smoking Cessation and Menstrual Cycle Phase (PHASE4)
- Cytisine vs Nicotine Replacement Therapy (NA)
- ACT Lung Health Intervention: Phase Two (NA)
- iCanQuit Smoking Cessation Among Hispanic Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |